文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

嗜酸性粒细胞性与非嗜酸性粒细胞性COPD急性加重及后续心血管事件

Eosinophilic vs Non-Eosinophilic Acute Exacerbations of COPD and Subsequent Cardiovascular Event.
PubMed 文献 · Chest · 2026-04-01
一句话结论回顾性队列显示,嗜酸性粒细胞性COPD急性加重患者1年主要不良心血管事件风险低于非嗜酸性粒细胞性患者(HR 1.22)。

该回顾性队列研究利用TriNetX数据库纳入2022年1月1日至2024年12月31日期间年龄≥40岁的COPD急性加重患者,嗜酸性粒细胞性急性加重定义为事件前后3天至1天内血嗜酸性粒细胞计数≥300/μL。共纳入143,517例患者(嗜酸性粒细胞性33,761例,非嗜酸性粒细胞性109,756例),倾向性评分1:1匹配后每组33,756例。随访1年,非嗜酸性粒细胞性组主要不良心血管事件风险高于嗜酸性粒细胞性组(HR 1.22,95%CI 1.17-1.26,P<.001),且嗜酸性粒细胞性组心力衰竭、急性心肌梗死、卒中、心律失常及全因死亡风险均降低。提示急性加重时血嗜酸性粒细胞计数可能有助于分层长期心血管风险。

要点

  • 嗜酸性粒细胞性COPD急性加重定义为事件前后3天至1天内血嗜酸性粒细胞计数≥300/μL。
  • 匹配后1年随访,非嗜酸性粒细胞性组主要不良心血管事件发生率高于嗜酸性粒细胞性组(5,967 vs 5,160例事件;HR 1.22,95%CI 1.17-1.26,P<.001)。
  • 嗜酸性粒细胞性急性加重与心力衰竭、急性心肌梗死、卒中、心律失常及全因死亡风险降低相关。
  • 敏感性分析(替代嗜酸性粒细胞阈值和地标时间窗)结果一致。
  • 急性加重时血嗜酸性粒细胞计数可能作为分层长期心血管风险的生物标志物。

适用人群与场景

  • 年龄≥40岁、2022年1月1日至2024年12月31日期间发生COPD急性加重的患者。
  • 嗜酸性粒细胞性急性加重:血嗜酸性粒细胞计数≥300/μL(事件前3天至事件后1天窗口内)。
  • 非嗜酸性粒细胞性急性加重:不符合上述嗜酸性粒细胞标准者。

诊断标准与关键阈值

  • 嗜酸性粒细胞性COPD急性加重:血嗜酸性粒细胞计数≥300/μL(事件前3天至事件后1天窗口内)。

研究设计与关键结果

  • 研究类型:回顾性队列研究,使用TriNetX Analytics Network数据库。
  • 样本量:共143,517例患者(嗜酸性粒细胞性33,761例,非嗜酸性粒细胞性109,756例);倾向性评分1:1匹配后每组33,756例。
  • 主要终点:1年主要不良心血管事件(心力衰竭、左心室射血分数降低、急性心肌梗死、脑梗死、心脏骤停、心律失常)。匹配后非嗜酸性粒细胞性组较嗜酸性粒细胞性组事件数5,967 vs 5,160,HR 1.22(95%CI 1.17-1.26),P<.001。
  • 关键次要终点:嗜酸性粒细胞性急性加重与心力衰竭、急性心肌梗死、卒中、心律失常及全因死亡风险降低相关。
  • Kaplan-Meier分析显示嗜酸性粒细胞性组无主要不良心血管事件生存率更高(log-rank检验 P<.001)。
  • 敏感性分析(阴性/阳性对照结局、替代嗜酸性粒细胞阈值、地标分析)结果一致。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,急性加重时血嗜酸性粒细胞计数可能作为分层COPD患者长期心血管风险的生物标志物,不仅用于肺部结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute exacerbation of COPD (AE-COPD) is associated with increased cardiovascular risk, but whether this risk differs between eosinophilic and non-eosinophilic AE-COPD remains unclear.

RESEARCH QUESTION: Is eosinophilic AE-COPD associated with a lower risk of major adverse cardiovascular events (MACEs)?

STUDY DESIGN AND METHODS: This retrospective cohort study was conducted by using the TriNetX Analytics Network. Patients aged ≥ 40 years with AE-COPD between January 1, 2022, and December 31, 2024, were included. Eosinophilic AE-COPD was defined as a blood eosinophil count ≥ 300/μL within the window of 3 days before to 1 day following the event. The primary outcome was the 1-year risk of MACEs (heart failure, reduced left ventricular ejection fraction, acute myocardial infarction, cerebral infarction, cardiac arrest, and arrhythmia). Propensity score matching (1:1) was performed, and Cox proportional hazards models and Kaplan-Meier analyses were used. Sensitivity analyses included negative/positive control outcomes, alternative eosinophil cutoff definitions, and landmark analyses.

RESULTS: A total of 143,517 patients were included (33,761 eosinophilic and 109,756 non-eosinophilic AE-COPD). After matching, 33,756 patients were retained in each group. During the 1-year follow-up, non-eosinophilic AE-COPD was associated with a higher risk of MACEs compared with eosinophilic AE-COPD (5,967 vs 5,160 events; hazard ratio, 1.22; 95% CI, 1.17-1.26; P < .001). Kaplan-Meier analysis confirmed higher MACE-free survival in patients with eosinophilic AE-COPD (log-rank test, P < .001). Eosinophilic AE-COPD was also associated with reduced risks of heart failure, acute myocardial infarction, stroke, arrhythmia, and all-cause mortality. Findings were consistent across sensitivity analyses, including alternative eosinophil thresholds and landmark time windows.

INTERPRETATION: Our results show eosinophilic AE-COPD was associated with a significantly lower risk of MACE compared with non-eosinophilic AE-COPD. Blood eosinophil count at the time of exacerbation may serve as a valuable biomarker for stratifying not only pulmonary outcomes but also long-term cardiovascular risk in COPD.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Lin CY, Zhong BK, Chou YT, et al. Eosinophilic vs Non-Eosinophilic Acute Exacerbations of COPD and Subsequent Cardiovascular Event. Chest. 2026. PMID: 41932679. doi:10.1016/j.chest.2026.03.023

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。